Skip to main content
. 2021 Jan 12;8:625943. doi: 10.3389/fcell.2020.625943

Table 1.

Ongoing clinical trials of IGF-1R inhibitors in cancers.

Drug Combination therapy Indicated diseases Phase NCT number Status#
Ganitumab
(AMG479)
- Metastatic or recurrent sarcoma 1 NCT04199026 NR
Combination chemotherapy Newly diagnosed metastatic Ewing sarcoma 3 NCT02306161 Ac/NR
Dasatinib Rhabdomyosarcoma 1/2 NCT03041701 R
Metformin Breast cancer 2 NCT01042379 R
Palbociclib Ewing sarcoma 2 NCT04129151 R
Cixutumumab
(IMC-A12)
Paclitaxel Metastatic esophageal cancer or gastroesophageal junction cancer 2 NCT01142388 Ac/NR
#

R, recruiting; Ac/NR, active not recruiting; NR, not yet recruiting.